AirNet Technology raises $180 million in digital assets offering
Raymond (NSE:RYMD) Dwek, a director at United Therapeutics Corp (NASDAQ:UTHR), a $12.5 billion market cap biotechnology company with excellent financial health and a perfect Piotroski Score of 9, executed a series of stock transactions on April 7, 2025, as disclosed in a recent SEC filing. Dwek sold 4,000 shares of United Therapeutics common stock at an average price of $284.55 per share, yielding approximately $1.14 million. According to InvestingPro analysis, the stock currently appears undervalued, with impressive gross profit margins of 89% and strong cash flows.
In conjunction with this sale, Dwek exercised stock options to acquire 4,000 shares at a price of $175.43 per share. These transactions were part of a pre-arranged 10b5-1 trading plan established on August 2, 2024. Get access to 12+ additional exclusive InvestingPro insights about UTHR's valuation and financial strength. Following these transactions, Dwek owns 1,750 shares directly.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, revealing a miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $6.19, falling short of the anticipated $6.68, while revenue reached $735.9 million, slightly below the forecasted $739.92 million. Despite the miss, United Therapeutics achieved record annual revenue growth for the third consecutive year, with key products like Tyvaso and Orenitram showing strong revenue increases of 19% and 28%, respectively. Additionally, Goldman Sachs analyst Chris Shibutani adjusted the price target for United Therapeutics to $293 from $302, maintaining a Neutral rating due to Tyvaso's underperformance and challenges from contracting efforts.
The company's recent developments include the early termination of the HYPERION study for Winrevair, with management asserting limited long-term impact. United Therapeutics continues to advance its pipeline with significant clinical trial progress, such as the anticipated first UKidney transplant around mid-2025 and outcomes from the IPF trials, TETON-2 and TETON-1, expected in late 2025 and early 2026, respectively. The company remains optimistic about its growth prospects, projecting continued double-digit revenue growth into the mid-decade. United Therapeutics did not provide financial guidance, consistent with their standard practice, and while further share repurchases could occur, no announcements regarding additional accelerated share repurchase plans were made.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.